Cyclopharm Limited (AU:CYC)
ASX:CYC
Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$1.48
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$106.53M
Enterprise ValueAU$118.60M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding126,065,790
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside2.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueCyclopharm's core Technegas model sells patient-dose consumables consumed per procedure, creating recurring, usage-linked revenue. An installed base of generators and ongoing service creates durable repeat sales and customer lock-in, supporting predictable long-term cash flows.
Consistent Revenue GrowthSteady top-line growth through 2025 demonstrates sustained commercial traction and increasing adoption of Technegas across imaging centres. Persistent revenue expansion over multiple years supports structural market penetration and underpins future scale if margins and costs are addressed.
Equity Buffer On Balance SheetA ~A$27.1m equity base provides a capital buffer to absorb operating losses and fund near-term operations. This balance-sheet cushion gives management time to execute commercial initiatives or regulatory steps without immediate insolvency risk, preserving optionality for restructuring or financing.
Bears Say
Negative Gross Profit And Widening LossesGross profit turning negative in 2025 signals costs exceeded revenue at the core product level, indicating structural margin weakness. Persistently negative gross margins undermine scalability, require material cost remediation or pricing changes, and threaten long-term profitability even with revenue growth.
High Cash Burn And Negative Operating Cash FlowSustained operating cash outflows (~A$-17.3m in 2025) and deeply negative free cash flow create ongoing funding needs. Persistent cash burn forces reliance on external financing or equity dilution, constraining the firm's ability to invest in commercialization or absorb shocks without eroding shareholder value.
Rising Leverage And Shrinking AssetsMaterial debt growth alongside declining equity increases financial risk and reduces flexibility. Higher leverage raises interest and refinancing exposure, may tighten covenants, and limits capacity to fund growth or respond to regulatory/market shifts without costly capital injections.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$1.48 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$106.53M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Sep 01, 2026 which is in 113 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 126,065,790 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (2.04% Upside)
AU$1.00 (2.04% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 92%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$75.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-54.48%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(2.04% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---